U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs

Lawmakers raising nationalist information concerns and seeking to disconnect a large Chinese steadfast from U.S. pharmaceutical interests person rattled the biotech industry. The steadfast is profoundly progressive successful improvement and manufacturing of important therapies for cancer, cystic fibrosis, H.I.V. and different illnesses.